These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30822264)

  • 1. Low-dose rt-PA may not decrease the incidence of symptomatic intracranial haemorrhage in patients with high risk of symptomatic intracranial haemorrhage.
    Liu M; Pan Y; Zhou L; Wang Y
    Neurol Res; 2019 May; 41(5):473-479. PubMed ID: 30822264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
    Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.
    Adeoye O; Knight WA; Khoury J; Schmit PA; Sucharew H; Broderick JP; Pancioli AM;
    J Stroke Cerebrovasc Dis; 2014; 23(5):e313-5. PubMed ID: 24534128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of post-thrombolysis symptomatic intracranial hemorrhage in Chinese patients with acute ischemic stroke.
    Liu M; Pan Y; Zhou L; Wang Y
    PLoS One; 2017; 12(9):e0184646. PubMed ID: 28922363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous Thrombolysis Is Safe and Effective for the Cryptogenic Stroke in China: Data From the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China).
    Fan Y; Liao X; Pan Y; Dong K; Wang Y; Wang Y;
    J Stroke Cerebrovasc Dis; 2019 Jan; 28(1):220-226. PubMed ID: 30366863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.
    Seet RC; Rabinstein AA
    Cerebrovasc Dis; 2012; 34(2):106-14. PubMed ID: 22868870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of antiplatelet pre-treatment on the risk of symptomatic intracranial haemorrhage after intravenous thrombolysis.
    Bravo Y; Martí-Fàbregas J; Cocho D; Rodríguez-Yáñez M; Castellanos M; de la Ossa NP; Roquer J; Obach V; Maestre J; Martí-Vilalta JL
    Cerebrovasc Dis; 2008; 26(2):126-33. PubMed ID: 18560215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who may benefit from lower dosages of intravenous tissue plasminogen activator? Results from a cluster data analysis.
    Dong Y; Han Y; Shen H; Wang Y; Ma F; Li H; Wang Y; Dong Q
    Stroke Vasc Neurol; 2020 Dec; 5(4):348-352. PubMed ID: 32611728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.
    Whiteley WN; Thompson D; Murray G; Cohen G; Lindley RI; Wardlaw J; Sandercock P;
    Stroke; 2014 Apr; 45(4):1000-6. PubMed ID: 24603072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generalized Safety and Efficacy of Simplified Intravenous Thrombolysis Treatment (SMART) Criteria in Acute Ischemic Stroke: The MULTI SMART Study.
    Sørensen SB; Barazangi N; Chen C; Wong C; Grosvenor D; Rose J; Bedenk A; Morrow M; McDermott D; Hove JD; Tong DC
    J Stroke Cerebrovasc Dis; 2016 May; 25(5):1110-1118. PubMed ID: 26897101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Study of Intravenous, Low-Dose Recombinant Tissue Plasminogen Activator for Acute Cerebral Infarction: Comparison of Treatment within 3 Hours versus 3-4.5 Hours.
    Deguchi I; Tanahashi N; Takao M
    J Stroke Cerebrovasc Dis; 2018 Apr; 27(4):1033-1040. PubMed ID: 29221968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.
    Al-Khaled M; Matthis C; Eggers J
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):7-11. PubMed ID: 22578915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator.
    Liu SY; Cao WF; Wu LF; Xiang ZB; Liu SM; Liu HY; Pan Y; Nie F; Wu XM; Xie XF
    Medicine (Baltimore); 2018 Dec; 97(49):e13216. PubMed ID: 30544380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptomatic intracerebral hemorrhage after intravenous thrombolysis in Chinese patients: comparison of prediction models.
    Li M; Wang-Qin RQ; Wang YL; Liu LB; Pan YS; Liao XL; Wang YJ; Xu AD
    J Stroke Cerebrovasc Dis; 2015 Jun; 24(6):1235-43. PubMed ID: 25891755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2 × 2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment.
    Huang Y; Sharma VK; Robinson T; Lindley RI; Chen X; Kim JS; Lavados P; Olavarría V; Arima H; Fuentes S; Nguyen HT; Lee TH; Parsons MW; Levi C; Demchuk AM; Bath PM; Broderick JP; Donnan GA; Martins S; Pontes-Neto OM; Silva F; Pandian J; Ricci S; Stapf C; Woodward M; Wang J; Chalmers J; Anderson CS;
    Int J Stroke; 2015 Jul; 10(5):778-88. PubMed ID: 25832995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of a new modified intravenous recombinant tissue plasminogen activator (rt-PA) regimen in Chinese patients with acute ischemic stroke: A descriptive retrospective cohort study with subgroup-analysis of different rt-PA dose.
    Luo Y; Li J; Huang L; Liu X; Zhang B; Lin J; Jiang A; Zhao J
    J Clin Neurosci; 2022 Jul; 101():244-251. PubMed ID: 35653882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Parameters for Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke in an Asian Population.
    Lokeskrawee T; Muengtaweepongsa S; Patumanond J; Tiamkao S; Thamangraksat T; Phankhian P; Pleumpanupatand P; Sribussara P; Kitjavijit T; Supap A; Rattanaphibool W; Prisiri J
    Curr Neurovasc Res; 2017; 14(2):169-176. PubMed ID: 28356002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study.
    Saqqur M; Shuaib A; Alexandrov AV; Sebastian J; Khan K; Uchino K
    Int J Stroke; 2015 Oct; 10(7):1087-92. PubMed ID: 26332252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Analysis on Low- and Standard-Dose Regimes of Alteplase Thrombolytic Therapy for Acute Ischemic Stroke: Efficacy and Safety.
    Zhao G; Huang T; Zheng M; Cui Y; Liu Y; Cheng Z; Wang Z
    Eur Neurol; 2018; 79(1-2):68-73. PubMed ID: 29241193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.